Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

Priovant Therapeutics secured FDA approval for its oral dual TYK2/JAK1 inhibitor brepocitinib, marketed as Lisraya, for adult patients with dermatomyositis, a rare autoimmune disease. The approval is based on positive phase 3 trial results demonstrating significant improvement in disease activity, with the drug offering a novel targeted treatment option for this underserved patient population.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 27 Aug 2026 and 2 Sep 2026.